Elan Pharmaceuticals Inc.

San Francisco, CA, United States

Elan Pharmaceuticals Inc.

San Francisco, CA, United States
SEARCH FILTERS
Time filter
Source Type

Global Nanotechnology Drug Delivery Systems Market by Technologies, Applications, Growth Trends and Forecast to 2021, New Report by iHealthcareAnalyst, Inc. Nanotechnology Drug Delivery Systems Market by Technology Types (Nanocrystals, Nanoparticles, Dendrimers, Gold Nanoparticles, Fullerenes, Liposomes, Micelles, Nanotubes), and Applications (Anti-Infective, Anti-Inflammatory, Immunology, Cardiovascular, Physiology, Neurology, Oncology) and Forecast 2017-2021 Maryland Heights, MO, April 28, 2017 --( Browse Nanotechnology Drug Delivery Systems Market by Technology Types (Nanocrystals, Nanoparticles, Dendrimers, Gold Nanoparticles, Fullerenes, Liposomes, Micelles, Nanotubes), and Applications (Anti-Infective, Anti-Inflammatory, Immunology, Cardiovascular, Physiology, Neurology, Oncology) and Forecast 2017-2021 at https://www.ihealthcareanalyst.com/report/nanotechnology-drug-delivery-systems-market/ The global nanotechnology drug delivery systems market segmentation is based on technology types (nanocrystals, nanoparticles, dendrimers, gold nanoparticles, fullerenes, liposomes, micelles, nanotubes), and its applications (anti-infective, anti-inflammatory, immunology, cardiovascular, physiology, neurology, oncology). The global nanotechnology drug delivery systems market report provides market size (Revenue USD Million 2014 to 2021), market share and forecasts growth trends (CAGR%, 2017 to 2021). The global nanotechnology drug delivery systems market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. The global nanotechnology drug delivery systems market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. Major players operating in the global nanotechnology drug delivery systems market and included in this report are AbbVie, Amgen, Celgene Corporation, Elan Pharmaceuticals, Johnson & Johnson, Pfizer, Inc., Merck & Co., Novartis AG, and Teva Pharmaceuticals. 1. Technology 1.1. Nanocrystals 1.2. Nanoparticles 1.3. Dendrimers 1.4. Gold Nanoparticles 1.5. Fullerenes 1.6. Liposomes 1.7. Micelles 1.8. Nanotubes 1.9. Others 2. Application 2.1. Anti-infective 2.2. Anti-inflammatory/Immunology 2.3. Cardiovascular/Physiology 2.4. Neurology 2.5. Oncology 2.6. Others 3. Geography (Region, Country) 3.1. North America (U.S., Canada) 3.2. Latin America (Brazil, Mexico, Rest of LA) 3.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU) 3.4. Asia Pacific (Japan, China, India, Rest of APAC) 3.5. Rest of the World 4. Company Profiles 4.1. AbbVie, Inc. 4.2. Amgen Inc. 4.3. Celgene Corporation 4.4. Johnson & Johnson 4.5. Merck & Co., Inc. 4.6. Novartis International AG 4.7. Perrigo Company plc 4.8. Pfizer, Inc. 4.9. Teva Pharmaceutical Industries Ltd. To request Table of Contents and Sample Pages of this report visit: https://www.ihealthcareanalyst.com/report/nanotechnology-drug-delivery-systems-market/ About Us iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals. In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study. Contact Us iHealthcareAnalyst, Inc. 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043 United States Email: sales@ihealthcareanalyst.com Website: https://www.ihealthcareanalyst.com Maryland Heights, MO, April 28, 2017 --( PR.com )-- Nanotechnology drug delivery systems involve the engineering of functional systems at the molecular scale, characterized by unique physical, optical and electronic features. Nanomedicine is a highly specific medical intervention for the prevention, diagnosis and treatment of diseases. Several anti-cancer drugs including paclitaxel, doxorubicin, 5-fluorouracil and dexamethasone have been successfully formulated using nanomaterials. Quantom dots, chitosan, Polylactic or glycolic acid (PLGA) and PLGA-based nanoparticles have also been used for in vitro RNAi delivery. The ability of nanotechnology to provide targeted drug delivery, improved solubility, extended half-life and reduce a drug’s immunogenicity has resulted in the potential to revolutionize the treatment of many diseases. Over the last two decades, significant progress has been made in the field of nanomedicine, resulting in a number of products, including therapeutics and imaging agents, enabling more effective and less toxic therapeutic and diagnostic interventionsBrowse Nanotechnology Drug Delivery Systems Market by Technology Types (Nanocrystals, Nanoparticles, Dendrimers, Gold Nanoparticles, Fullerenes, Liposomes, Micelles, Nanotubes), and Applications (Anti-Infective, Anti-Inflammatory, Immunology, Cardiovascular, Physiology, Neurology, Oncology) and Forecast 2017-2021 at https://www.ihealthcareanalyst.com/report/nanotechnology-drug-delivery-systems-market/The global nanotechnology drug delivery systems market segmentation is based on technology types (nanocrystals, nanoparticles, dendrimers, gold nanoparticles, fullerenes, liposomes, micelles, nanotubes), and its applications (anti-infective, anti-inflammatory, immunology, cardiovascular, physiology, neurology, oncology). The global nanotechnology drug delivery systems market report provides market size (Revenue USD Million 2014 to 2021), market share and forecasts growth trends (CAGR%, 2017 to 2021). The global nanotechnology drug delivery systems market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. The global nanotechnology drug delivery systems market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.Major players operating in the global nanotechnology drug delivery systems market and included in this report are AbbVie, Amgen, Celgene Corporation, Elan Pharmaceuticals, Johnson & Johnson, Pfizer, Inc., Merck & Co., Novartis AG, and Teva Pharmaceuticals.1. Technology1.1. Nanocrystals1.2. Nanoparticles1.3. Dendrimers1.4. Gold Nanoparticles1.5. Fullerenes1.6. Liposomes1.7. Micelles1.8. Nanotubes1.9. Others2. Application2.1. Anti-infective2.2. Anti-inflammatory/Immunology2.3. Cardiovascular/Physiology2.4. Neurology2.5. Oncology2.6. Others3. Geography (Region, Country)3.1. North America (U.S., Canada)3.2. Latin America (Brazil, Mexico, Rest of LA)3.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)3.4. Asia Pacific (Japan, China, India, Rest of APAC)3.5. Rest of the World4. Company Profiles4.1. AbbVie, Inc.4.2. Amgen Inc.4.3. Celgene Corporation4.4. Johnson & Johnson4.5. Merck & Co., Inc.4.6. Novartis International AG4.7. Perrigo Company plc4.8. Pfizer, Inc.4.9. Teva Pharmaceutical Industries Ltd.To request Table of Contents and Sample Pages of this report visit:https://www.ihealthcareanalyst.com/report/nanotechnology-drug-delivery-systems-market/About UsiHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study.Contact UsiHealthcareAnalyst, Inc.2109, Mckelvey Hill Drive,Maryland Heights, MO 63043United StatesEmail: sales@ihealthcareanalyst.comWebsite: https://www.ihealthcareanalyst.com


Probst G.,Elan Pharmaceuticals Inc. | Xu Y.-Z.,Elan Pharmaceuticals Inc.
Expert Opinion on Therapeutic Patents | Year: 2012

Introduction: Alzheimer's disease is a devastating neurodegenerative disorder for which no disease-modifying therapy exists. The amyloid hypothesis, which implicates Aβ as the toxin initiating a biological cascade leading to neurodegeneration, is the most prominent theory concerning the underlying cause of the disease. BACE1 is one of two aspartyl proteinases that generate Aβ, thus inhibition of BACE1 has the potential to ameliorate the progression of Alzheimer's disease by abating the production of Aβ.Areas covered: This review chronicles small-molecule BACE1 inhibitors as described in the patent literature between 2006 and 2011 and their potential use as disease-modifying treatments for Alzheimer's disease. Over the past half a dozen years, numerous BACE1 inhibitors have been published in the patent applications, but often these contain a paltry amount of pertinent biological data (e.g. potency, selectivity, and efficacy). Fortunately, numerous relevant publications containing important data have appeared in the journal literature during this period. The goal in this effort was to create an amalgam of the two records to add value to this review.Expert opinion: The pharmaceutical industry has made tremendous progress in the development of small-molecule BACE1 inhibitors that lower Aβ in the central nervous system. Assuming the amyloid hypothesis is veracious, we anticipate a disease-modifying therapy to combat Alzheimer's disease is near. © 2012 Informa UK, Ltd.


Patent
Elan Pharmaceuticals Inc. and Foundation University | Date: 2014-05-14

Methods useful for effecting prophylaxis or treatment of amyloidosis, including AA Amyloidosis and AL amyloidosis, by administering peptides comprising neoepitopes, such as AA fragments from a C-terminal region of AA, and antibodies specific for neoepitopes of aggregated amyloid proteins, for example, antibodies specific for the C-terminal region of AA fibrils. Antibodies for inhibition of formation and/or increasing clearance of amyloid deposits in a patient thus effecting prophylaxis or treating amyloid disease.


Patent
Foundation University and Elan Pharmaceuticals Inc. | Date: 2013-12-06

Methods useful for effecting prophylaxis or treatment of amyloidosis, including AA Amyloidosis and AL amyloidosis, by administering peptides comprising neoepitopes, such as AA fragments from a C-terminal region of AA, and antibodies specific for neoepitopes of aggregated amyloid proteins, for example, antibodies specific for the C-terminal region of AA fibrils. Antibodies for inhibition of formation and/or increasing clearance of amyloid deposits in a patient thus effecting prophylaxis or treating amyloid disease.


Disclosed is a process for preparing polymer conjugates of agricultural, therapeutic, and food additive compounds using Mitsunobu conditions.


Alpha 4 inhibitors are used in treatment of inflammatory and autoimmune diseases, such as multiple sclerosis, Crohns Disease, rheumatoid arthritis and asthma. Rare occurrences of progressive multifocal leucoencephalopathy during treatment with an alpha-4 agent suggest the possibility that it may be related to such treatment. Monitoring for the JC virus and educating caregivers and patients about the manifestations of progressive multifocal leucoencephalopathy can improve the safety of alpha 4 inhibitor therapy.


Patent
Biogen Idec and Elan Pharmaceuticals Inc. | Date: 2013-10-02

The invention relates to methods and products for the identification of a clinically significant immune response in subjects treated with a therapeutic protein. Aspects of the invention relate to methods and compositions for identifying a clinically significant immune response in patients treated with therapeutic amounts of a VLA4 binding antibody (e.g., natalizumab).


Compounds are provided having a structure according to Formula (I): wherein A_(1), A_(2), A_(3), Y, R^(1), R^(2), R^(3), R^(4), R^(5), R^(6), m, n and p are defined herein. Further provided are pharmaceutical compositions including the compounds provided and methods of making and using the compounds and compositions as provided, e.g., in the treatment and prevention of various disorders, such as Alzheimers disease.


Patent
Elan Pharmaceuticals Inc. | Date: 2015-01-14

The present invention provides compounds having a structure according to Formula (I): or a salt or solvate thereof, wherein ring A, X, R^(1), R^(2), R^(3), R^(4), R^(5 )and R^(6), are defined herein. The invention further provides pharmaceutical compositions including the compounds of the invention and methods of making and using the compounds and compositions of the invention, e.g., in the treatment and prevention of various disorders, such as Parkinsons disease.


Patent
Elan Pharmaceuticals Inc. | Date: 2014-03-12

The present invention provides compounds having a structure according to Formula I. The invention further provides pharmaceutical compositions including the compounds of the invention and methods of making and using the compounds and compositions of the invention, e.g., in the treatment and prevention of various disorders, such as Parkinsons disease.

Loading Elan Pharmaceuticals Inc. collaborators
Loading Elan Pharmaceuticals Inc. collaborators